Identification of Substrate-selective Histone Deacetylases and Their Inhibitors That Mediate HER2 Transcript Stability

Identification of Substrate-selective Histone Deacetylases and Their Inhibitors That Mediate HER2 Transcript Stability

Website or Online Data - 2018
Rate this:
Breast cancer is the most common malignancy diagnosed in women. 15-20% of these cancers overexpress the HER2 (ERRB2) oncoprotein. HER2-positive breast cancers are generally aggressive and are associated with poor prognosis. Unfortunately, only a mere 30% of HER2-positve patients respond to therapies when they are used as a single agent. Combining therapeutics can potentially lead to synergy and improved anticancer efficacy, and there is clearly a need for the development of new HER2-directed therapeutics. Newer approaches include the utilization of histone deacetylase (HDAC) inhibitors. It has been observed that HDAC inhibitors can induce the rapid decay of oncogenic transcripts such as the HER2 mRNA, though the mechanism underlying this process remains undefined. Earlier observations in our lab led to speculation that protein(s) binding the 3'-untranslated region (UTR) of HER2 mRNA become acetylated following HDAC inhibitor treatment and promote the HER2 mRNA decay while engaged in the translational machinery. Pursuing this speculation, a key ribosome- or polyribosome-associated candidate suspected of interacting with and mediating this HER2 mRNA decay became a protein identified by mass spectrometry in cytosolic fractions containing rapidly degrading HER2 mRNA as a protein appearing hyper-acetylated within hours of breast cancer cell exposure to a pan-HDAC inhibitor. Studies conducted using pan-HDAC inhibitors like Trichostatin A (TSA) as well as various class-selective HDAC inhibitors, examine their comparative influences on the association of proteins with either the ribosome or polyribosome translational machinery, protein levels and acetylation status before and after HDACi treatment, and their functional impact on HER2 mRNA by modulating its expression levels. Understanding the mechanism by which optimal class-selective HDAC inhibitors modulate translation-associated proteins to facilitate HER2 mRNA degradation will allow for more effective use of HDAC inhibitor's antitumor activity to combat HER2-positive breast cancers
Publisher: San Rafael, Calif. : Dominican University of California, 2018
Characteristics: 1 volume (electronic resource)

Opinion

From the critics


Community Activity

Comment

Add a Comment

There are no comments for this title yet.

Age

Add Age Suitability

There are no ages for this title yet.

Summary

Add a Summary

There are no summaries for this title yet.

Notices

Add Notices

There are no notices for this title yet.

Quotes

Add a Quote

There are no quotes for this title yet.

Explore Further

Recommendations

Subject Headings

  Loading...

Find it at MARINet

  Loading...
[]
[]
To Top